$72.09 -$0.41 (-0.6%)

04:00 PM EST on 11/21/19

Davita Healthcare Partners, Inc. (NYSE:DVA)

CAPS Rating: 4 out of 5

The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.

Current Price $72.09 Mkt Cap $9.4B
Open $72.40 P/E Ratio 28.27
Prev. Close $72.50 Div. (Yield) $0.00 (0.0%)
Daily Range $71.70 - $72.77 Volume 533,215
52-Wk Range $43.40 - $72.82 Avg. Daily Vol. 1,610,882

Caps

How do you think NYSE:DVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

387 Outperform
18 Underperform
 

All-Star Players

74 Outperform
6 Underperform
 

Wall Street

13 Outperform
2 Underperform
 

Top NYSE:DVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

tidehunter (< 20)
Submitted June 11, 2014

A long-term experiment to see if riding on Buffett's coattails really gets me anywhere.

Madder123458 (< 20)
Submitted January 06, 2016

Although DaVita has large market share and high pricing power, they have used their semi-monopolistic position in the market to demand high premiums and annual "rate inflators" that keep their rates compounding upwards. Because of this heavy-handed… More

Recent Community Commentary

Read the most recent pitches from players about DVA.

Recs

0
Member Avatar AllTooFoolish (71.27) Submitted: 6/3/2019 12:38:10 PM : Outperform Start Price: $45.27 NYSE:DVA Score: +46.16

Current BI Downside Price Target -22%

Recs

1
Member Avatar Madder123458 (< 20) Submitted: 1/5/2016 11:28:36 PM : Underperform Start Price: $68.22 NYSE:DVA Score: +50.80

Although DaVita has large market share and high pricing power, they have used their semi-monopolistic position in the market to demand high premiums and annual "rate inflators" that keep their rates compounding upwards. Because of this heavy-handed approach, insurance companies have them on their radar as a high cost provider that the recent slew of consolidations will target for savings. And once one of the big insurance companies gets a rate concession from them, there will be chum in the water and the others will be looking for the same.

Also, they had a pretty simple, stable dialysis business model. With their foray into broader healthcare with HCP, they don't have the expertise or infrastructure to run that more complicated business profitably yet. And with pricing pressure on the Medicare side of things, that business will have to adapt quickly to make them a good return on their investment.

Recs

0
Member Avatar jeff1339 (< 20) Submitted: 6/23/2015 5:27:44 PM : Outperform Start Price: $81.55 NYSE:DVA Score: -58.18

Expectation of continued growth in demand for their services as the population ages. Greatest risk is a potential drug breakthrough, that would make their services obsolete.

Leaderboard

Find the members with the highest scoring picks in DVA.

Score Leader

TrackJimCramer

TrackJimCramer (86.96) Score: +194.93

The Score Leader is the player with the highest score across all their picks in DVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
coolMD 35.59 2/18/2009 Underperform NS $25.38 +184.09% +299.21% +115.12 0 Comment
abber24 41.02 3/25/2008 Outperform NS $22.10 +226.20% +138.65% +87.55 0 Comment
zoehendricks 35.39 3/24/2008 Outperform NS $22.36 +222.48% +137.30% +85.18 0 Comment
anitaS83 < 20 3/24/2008 Outperform NS $22.37 +222.33% +137.44% +84.89 0 Comment
marvin1234 < 20 3/24/2008 5/28/2008 Outperform 3M $22.58 +219.26% +141.42% +77.85 1 Comment
LazyTimeMoney 69.14 3/25/2008 Outperform NS $22.83 +215.84% +138.00% +77.84 0 Comment
televester 86.98 3/17/2008 Outperform NS $21.66 +232.90% +155.53% +77.37 0 Comment
Vend01 26.40 3/14/2008 Outperform 1Y $22.67 +218.00% +143.59% +74.41 1 Comment
eatpb < 20 3/14/2008 Outperform 3Y $22.22 +224.51% +150.59% +73.92 0 Comment
coach1937 < 20 3/12/2008 Outperform NS $22.89 +215.01% +143.33% +71.68 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for DVA.